A supplemental application for Enhertu (fam-trastuzumab deruxtecan-nxki) received FDA approval for efficacy on 2026-04-27. This approval, designated BLA 761139 S-39, was granted to sponsor DAIICHI SANKYO, signifying an expansion of the drug's approved therapeutic profile.

Background

Enhertu (trastuzumab deruxtecan) is an antibody-drug conjugate. This specific event marks a supplemental efficacy approval from the FDA. Supplemental applications are submitted for various reasons, including adding a new indication, a new patient population, a new dosage regimen, or a new manufacturing process. In this case, the approval is specifically for efficacy, meaning new clinical data supported the drug's effectiveness for an expanded or modified use. Such approvals are crucial for broadening the utility of established medications and making them available to more patients who may benefit.

What this means

The FDA's supplemental approval for Enhertu's efficacy on 2026-04-27 indicates that new clinical evidence has demonstrated the drug's effectiveness for an additional or modified use. While the precise details of the new indication or patient population are not specified in the provided data, this type of approval typically allows healthcare providers to consider Enhertu for a wider array of clinical scenarios than previously approved. This can lead to significant changes in treatment guidelines and patient management strategies, potentially offering new therapeutic options for patients who previously had limited choices. For clinicians, understanding these expanded approvals is key to optimizing patient care and ensuring access to the most current treatment options. Researchers may also find this approval relevant for guiding future studies into the drug's mechanisms or applications in other disease states.

Source

The information regarding this supplemental FDA approval was obtained from the official FDA website, which serves as a primary source for regulatory actions concerning pharmaceutical products. The approval for BLA 761139 S-39 for Enhertu (fam-trastuzumab deruxtecan-nxki), sponsored by DAIICHI SANKYO, was posted on 2026-04-27 on accessdata.fda.gov. This public record provides transparent access to regulatory decisions for clinicians, researchers, and the public.